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Abstract 
Rationale: MicroRNAs are small non-coding RNAs involved in the regulation of gene expression and 
have recently been implicated in the development of pulmonary arterial hypertension (PAH). Previous 
work established that miR-451 is up-regulated in rodent models of PAH.  
Objectives: The role of miR-451 in the pulmonary circulation is unknown. We therefore sought to assess 
the involvement of miR-451 in the development of pulmonary arterial hypertension. 
Methods: Silencing of miR-451 was performed in vivo using miR-451 knockout mice and an antimiR 
targeting mature miR-451 in rats. Coupled with exposure to hypoxia, indices of pulmonary arterial 
hypertension were assessed. The effect of modulating miR-451 on human pulmonary artery smooth 
muscle cell proliferation and migration was analysed. 
Measurements and Main Results: We observed a reduction in systolic right ventricular pressure in 
hypoxic rats pre-treated with antimiR-451 compared to hypoxia alone (47.7 ± 1.36mmHg and 56.0 ± 
2.03mmHg respectively, p<0.01).  In miR-451 knockout mice following exposure to chronic hypoxia, no 
significant differences were observed compared to wild type hypoxic mice. In vitro analysis demonstrated 
that over-expression of miR-451 in human pulmonary artery smooth muscle cells promoted migration 
under serum-free conditions. No effect on cellular proliferation was observed. 
Conclusions: Transient inhibition of miR-451 attenuated the development of pulmonary arterial 
hypertension in hypoxia exposed rats. Genetic deletion of miR-451 had no beneficial effect on indices of 
pulmonary arterial hypertension, potentially due to pathway redundancy compensating for the loss of 
miR-451. 
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Key Messages: Over-expression of miR-451 in human pulmonary artery smooth muscle cells promotes 
smooth muscle cell migration in the absence of serum and in vivo data suggests that acute knockdown of 
miR-451 in male rats may be protective in the development of PAH. 
 
Introduction 
Pulmonary arterial hypertension (PAH) is a complex disease characterised by narrowing of the pulmonary 
arteries leading to an elevation in pulmonary artery pressure, right ventricular failure and can result in 
premature death.[1] Distinguishing features of this condition include endothelial cell proliferation and 
apoptosis resulting in the formation of plexiform lesions, fibroblast proliferation, production of matrix 
proteins and muscularisation of normally non-muscular arteries culminating in remodelling of the vessel 
wall.[2] Current therapies for PAH aim to reverse the endothelial dysfunction and vasoconstriction 
observed [3] however, these treatments do not prevent the aggressive progression of the disease and 
mortality rates remain unacceptably high. Therefore greater understanding of the pathways involved in 
PAH development and maintenance is required to more effectively manage PAH. 
 
Recent work has highlighted the importance of small non-coding RNA molecules called microRNAs 
(miRNAs) in the development of PAH.[4-5] Mature miRNAs are approximately 22 nucleotides long and 
negatively regulate gene expression by entering the RNA induced silencing complex (RISC). The miRNA 
then binds to the 3’-UTR of the mRNA leading to cleavage of target mRNA or translational repression.[6] 
MiRNAs in general regulate numerous mRNAs therefore by targeting one specific miRNA, a range of 
cellular pathways can potentially be modulated. MiRNAs are expressed at varying levels in a tissue-
specific pattern throughout the body. [7-8] Previous studies have shown that miRNAs play a role in the 
lung during the development of PAH. For example, down regulation of miR-204 has been observed in 
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pulmonary artery smooth muscle cells (PASMCs) in both rodent and human PAH and this down-
regulation is believed to play a role in stimulating proliferation and inhibiting apoptosis in PASMCs.[9] 
Conversely, miR-145 is found to be up-regulated during the development of PAH and knock down of 
miR-145 expression in vivo has been shown to be protective against the development of PAH.[10] 
 
A study carried out by Caruso and colleagues [4] found that miR-451 was up-regulated in the lung of two 
rodent models of PAH. MiR-451 is processed in a dicer-independent manner where the precursor stem 
loop miRNA is short and can be cleaved directly by Ago2 to be incorporated into the RISC complex.[11-12] 
MiR-451 is known to play a pivotal role in erythroid maturation. MiR-451 levels are significantly 
increased in erythroid precursors and remain elevated throughout erythroid differentiation [13] with mice 
lacking miR-451 unable to effectively develop mature circulating red blood cells in response to stress [14-
15] resulting in erythoid hyperplasia.[16] MiR-451 has also been implicated in a variety of cancer-related 
pathways.[17-21] It has been reported that miR-451 is down regulated in tissue from non-small cell lung 
carcinoma (NSCLC) and over-expression of miR-451 in vitro suppressed proliferation and colony 
formation of these cells by down-regulating RAB14 protein.[19] It has also been found that miR-451 acts 
as a tumour suppressor in T cell acute lymphoblastic leukemia via targeting of Myc, a proto-oncogene 
which is essential for Notch-1 induced tumour formation.[20] Similarly, miR-451 was observed to reduce 
gastric and colorectal cancer cell proliferation by down-regulating macrophage migration inhibitory factor 
[21] thus providing further evidence of miR-451 acting as a tumour suppressor. Recent work has 
highlighted the role of miR-451 in cardiac disease development with an up-regulation of miR-451 
observed to be cardioprotective against hypoxic stress in cardiomyocytes.[22] Likewise, knockdown of the 
miR-451 cluster prevents cardioprotection initiated by ischemic preconditioning in mice by up-regulating 
RAC1 and thus activating oxidative stress pathways.[23]  
 
Knowledge of the role of miR-451 in the development of PAH is largely unknown and microRNAs 
appear to play an important role in the pathogenesis of PAH. We therefore sought to modulate miR-451 
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both in vivo and in vitro to assess the functional role of miR-451 in the development of pulmonary arterial 
hypertension. 
 
Methods 
MiR-451 overexpression in human pulmonary artery smooth muscle cells 
Human pulmonary artery smooth muscle cells (hPASMCs, Lonza Group Ltd, Basel, Switzerland) were 
transfected with a miR-451 mimic (Ambion, Carlsbad, CA) or control miR mimic using siPORT neoFX 
transfection reagent (Invitrogen, Carlsbad, CA). Migration of hPASMCs was analysed using the scratch 
wound assay. Briefly, cells were simultaneously transfected with 10 nM miR mimic and plated in a 6-
well plate at a density of 4.5x105cells/well using siPORT neoFX reverse transfection protocol. Once 
confluent, cells were quiesced in 0.1% serum media for 48h. Vertical scratches were drawn through the 
confluent monolayer, media replaced with 0.1% or 15% serum containing media and scratches analysed 
at 0, 6, 12 and 24h using ImageJ software. Independent experiments were performed three times, with two 
wells and four scratches per well for each condition. DNA synthesis of hPASMCs was assessed using a 
thymidine incorporation assay where cells were plated in a 24-well plate at a density of 2x104cells/well 
and grown to ~50% confluency. Cells were quiesced in 0.1% serum for 48h and then transfected with 10 
nM miR mimic. Differing serum concentrations (0.1%, 2.5% and 10% serum) were added to the cells for 
72h with 3H-thymidine added for the last 24h. Radioactivity was measured using a liquid scintillation 
counter and results expressed in counts per minute (cpm). 
 
Animal Models 
All protocols and surgical procedures were approved by the local animal care committee. Animal 
experiments were conducted in accordance with the Animals Scientific Procedures Act UK 1986. Male 
wistar rats (aged 8 weeks) were administered antimiR-451 (miRagen Therapeutics Inc, Colorado and 
consisting of LNA and DNA bases of the complementary reverse sequence bases 2-17 of miR-451) or a 
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non-targeted antimiR control (similar composition to the antimiR but directed against a miRNA in 
C.elegans) intravenously at a dose of 10mg/kg. After three days recovery, animals were exposed to 
normoxic (21% O2) or hypoxic (10% O2) conditions for 7 days. The 7 day exposure to hypoxia was 
chosen as previous data had shown upregulation of miR-451 at this time point.[4] Pulmonary pressures 
were taken on day 7 and right ventricular hypertrophy was assessed by dissection of the heart (right 
ventricle (RV)/left ventricle + septum (LV+S)). 
 
Female miR-451 wild type and knockout mice (kindly supplied by Eric Olson, UT Southwestern, USA) 
were exposed to normoxic (21% O2) or hypoxic (10% O2) conditions for 14 days with pulmonary 
pressures taken on day 14 (at 10 weeks of age) along with right ventricular hypertrophy assessment. 
Female mice were chosen to study as previous work from our laboratory has shown that PAH is more 
prominent in female transgenic mice compared to male mice.[24-26] 
 
For remodelling analysis, lung sections were stained with elastic Van Gieson stain and the percentage of 
remodelled vessels assessed. Pulmonary arteries of d 80 microns in diameter were counted as remodelled 
if they consisted of a double elastic lamina for more than half of the diameter of the vessel. The 
percentage of remodelled vessels was calculated as the number of remodelled vessels/total number of 
vessels x 100. Lung sections from 4-6 animals were assessed per group.  
 
Gene targets for miR-451 
A list of targets was obtained for miR-451 by searching the miRNA databases miRwalk 
(http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk) and TargetScan (http://www.targetscan.org). 
Target genes for analysis were chosen based on previous knowledge of the predicted target genes and 
their involvement in pathways thought to be important in the development of PAH. Target mRNA 
expression was assessed in the same samples used for miRNA analysis using quantitative real-time 
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polymerase chain reaction (qRT-PCR) assay kits (Applied Biosystems, Carlsbad, CA) with results being 
normalised to beta-2-microglobulin (B2M). 
 
miRNA expression 
Expression levels of miR-451 and miR-144 were analysed in the lung and other tissues by qRT-PCR with 
results being normalized to U87, U6 and RNU48 for rat, mouse and human samples, respectively. 
Northern blot analysis was performed using hsa-miR-451 miRCURY LNA 5’-DIG labelled detection 
probe (Exiqon, Vedbaek, Denmark) and a hybridization temperature of 50ºC, with band intensities 
normalized against U6 band intensity.  
 
Statistical analysis 
All qRT-PCR results are expressed as fold change ± SEM with all other results expressed as the mean ± 
SEM. A 2-way ANOVA followed by Bonferroni post-hoc test or 1-way ANOVA followed by Tukey’s 
post-hoc test were used to analyse data as appropriate, with statistical significance accepted at p<0.05. 
 
Results 
Modulation of miR-451 in hPASMCs 
The development of PAH is characterised by phenotypic changes in smooth muscle cells (SMC) and 
endothelial cells (EC) within the medial and intimal layers.[27] Due to their role in the remodelling process 
observed during PAH, hPASMCs were focused on and the effect of modulating miR-451 expression in 
hPASMCs on phenotypic characteristics of PAH was investigated. Therefore miR-451 “mimics” were 
used to over-express miR-451 in vitro in hPASMCs. The miR mimic was tested over a variety of 
concentrations and miR-451 expression levels were increased significantly at all concentrations compared 
to the control mimic and mock transfected cells (Figure 1A). Since all concentrations produced efficient 
over-expression, 10 nM was used in all subsequent experiments and further evaluated by northern blot 
analysis (Figure 1B). The effect of miR-451 on proliferation of hPASMCs was assessed. Increasing 
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concentrations of serum induced a consistent increase in DNA synthesis in control and mock transfected 
cells (Figure 1C). This pattern was also observed in hPASMCs over-expressing miR-451 as proliferation 
was not altered in the absence or presence of serum, indicating that miR-451 does not affect proliferation 
in these cells under experimental conditions tested.  
 
The effect of over-expressing miR-451 on the migration of hPASMCs was also examined as migration of 
SMCs into previously non-muscular arteries plays a major role in PAH development.[2] In cells 
transfected with control mimic stimulated with 15% serum, the wound was completely closed after 24h 
(Figure 1D, F). Similarly, cells transfected with miR-451 mimic and stimulated with 15% serum were no 
different to control mimic transfected cells indicating that miR-451 does not inhibit serum induced 
migration of hPASMCs. In the presence of 0.1% serum, cells transfected with miR-451 mimic showed 
significantly smaller wounds than those observed in the mock and control mimic cells at 24h (Figure 1D, 
E), thus suggesting that miR-451 promotes migration of hPASMCs in the absence of serum.  
 
Modulation of miR-451 using antimiR-451 in vivo 
We next assessed the contribution of miR-451 to hypoxic-induced vascular remodelling and PAH in vivo 
using a pharmacological inhibitor approach. To verify the degree of knock-down obtained using an 
antimiR targeting mature miR-451 in vivo, tissues were harvested from rat following 7 days hypoxic 
exposure and miR-451 expression levels analysed. MiR-451 expression was extremely low in all tissues 
treated with antimiR-451 compared to the control treated tissues (Figure 2A, C, D) demonstrating that the 
antimiR reduced miR-451 expression globally. MiR-451 is located on chromosome 10 in rats and is 
transcribed together with miR-144 as a bicistronic primary transcript which is processed to generate the 
two separate mature miRNAs.[28] Expression levels for miR-144 were also analysed by qRT-PCR (Figure 
2B). MiR-144 expression increased significantly in RBCs when exposed to hypoxia however, there were 
no significant differences between control and antimiR-451 treated animals in either normoxic or hypoxic 
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conditions in any of the tissues analysed, hence indicating that antimiR-451 selectively down-regulates 
miR-451 in vivo. 
 
The effect of silencing miR-451 on PAH development was then investigated. Heart rate was unchanged 
between groups (Figure 3A). Rats exposed to hypoxia and control antimiR had a significant increase in 
systolic right ventricular pressure (RVP) compared to normoxic animals, while pre-treatment with 
antimiR-451 prior to hypoxic exposure lowered the RVP compared to control antimiR treated animals 
(Figure 3B). There was no significant difference between right ventricular hypertrophy (RVH) 
measurements between groups (Figure 3C). There was an increase in remodelling (Figure 3D, E) in all 
hypoxic animal groups compared with normoxic controls. Administration of antimiR-451 did not 
significantly reduce vessel remodelling.  
 
Analysis of miR-451 targets 
The reduction in RVP in hypoxic conditions when animals were pre-treated with antimiR-451 (Figure 3B) 
is most likely due to derepression of target genes regulated by miR-451. Target prediction algorithms 
miRWalk and TargetScan were used along with searching the literature to select target genes for miR-451. 
Previous studies have shown using different tissues along with target data analysis software that miR-451 
targets genes including Akt1 and Bcl2,[19, 29] Rac1,[23] Tbx1 [30] and Ywhaz. [31-32] These genes were 
therefore chosen to analyse using mRNA extracted from the whole lung of antimiR-451 and control 
treated animals (Figure 4A-E). Three of the chosen genes; Akt1, Rac1 and Ywhaz showed a significant 
down-regulation when miR-451 was knocked down, while none of the genes investigated showed 
derepression in antimiR-451 treated animals. This suggests that miR-451 modulation in PAH affects 
alternate pathways.  
 
Effect of miR-451 knockout mice on PAH development 
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We then assessed the effect of chronic knockdown of miR-451 on the development of PAH with the use 
of miR-451 knockout mice. Mice were exposed to hypoxic conditions for 14 days at 8 weeks of age (with 
age-matched wild type control mice) after which, in vivo measurements were taken. qRT-PCR and 
northern blot analysis of tissue taken from these animals confirmed the absence of miR-451 in lung tissue 
(Figure 5A, C, D). MiR-144 levels were also analysed and were unchanged between wild type and 
knockout mice (Figure 5B), although interestingly this miRNA was decreased in response to hypoxia. 
Assessment of PAH indices were performed along with heart rate measurements. No difference in heart 
rate was observed between groups (Figure 5E). RVP, RVH and remodelling showed the expected increase 
in wild type animals in response to hypoxia (Figure 5F-H). Knockout animals exposed to hypoxia 
demonstrated comparable RVP values to hypoxic wild type animals (Figure 5F) with similar results in 
RVH and remodelling analysis (Figure 5G, H). Target gene analysis was performed on mRNA extracted 
from whole lung. No significant up-regulation was observed in the knockout mice compared to wild type 
mice although we did observe that a number of these targets were modulated by hypoxia (Figure 6A-F).   
 
Discussion 
The role of miR-451 in the lung is largely unknown. The involvement of miR-451 in the development of 
PAH was assessed in this study using both in vivo and in vitro studies. We show that over-expression of 
miR-451 in hPASMCs promotes migration in the absence of serum but has no effect on proliferation. In 
vivo data suggests that acute knockdown of miR-451 in male rats diminishes aspects of the PAH 
phenotype while genetic ablation of miR-451 has no beneficial effect.  
 
One of the main characteristics of PAH is muscularisation of formally non-muscular arteries and 
remodelling of the pulmonary vessels.[33] Smooth muscle cells are one of the principle cell types involved 
in this process and phenotypic dysregulation of PASMC proliferation and migration contributes to the 
complex remodelling observed in PAH. In this study, over-expression of miR-451 promoted hPASMC 
migration. Hence this may be one of the factors leading to increased muscularisation of the vessel during 
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the early development of PAH. Cell culture studies, however, showed no effect of over-expressing miR-
451 on hPASMC proliferation. Of course, it is clear that a number of divergent pathways can lead to 
dysregulation of PASMC proliferation.[34-35] Certainly, under the experimental conditions studied here, 
including over-expression to very high levels using a mimic-based approach, we observed no effect of 
miR-451 manipulation on hPASMC proliferation.  
 
Analysis of miR-451 target genes did not show derepression of any of the genes of interest in both the 
antimiR-451 treated rats and the miR-451 knockout mice. MiR-451 has relatively few validated or 
predicted targets and highlighting the genes which are genuine targets presents a challenge. In this study, 
target prediction algorithms were used along with searching the literature for targets of miR-451. Wang 
and colleagues [23] demonstrated that miR-451 targets Rac1 in the heart to mediate the cardioprotection 
observed in ischemic preconditioning. In this system, miR-451 represses target gene Rac1 therefore 
inhibiting the production of reactive oxygen species and causing damage to the heart tissue. Similarly, 
other studies [31-32] have found that miR-451 targets Ywhaz (14-3-3¶) in erythroblasts. Repression of 
Ywhaz by miR-451 releases the inhibitory effect of Ywhaz on the transcription factor FoxO3, which 
regulates anti-oxidant genes. Both of these miR-451 target genes are involved in the regulation of reactive 
oxygen species production which is known to be upregulated in the lung during hypoxia and pulmonary 
arterial hypertension.[36] However, these target genes have been identified in different tissues and different 
disease models, indicating that miR-451 may not directly target these genes in the lung during the 
development of PAH. Further work is required to give a more comprehensive understanding of the 
pathways involved in miR-451 modulation during PAH development, such as microRNA microarrays or 
a proteomics-based approach. 
 
Global and selective knock-down of miR-451 was achieved using an antimiR-451. MiR-451 is known to 
play an essential role in normal erythroid differentiation. [15-16, 31, 37] AntimiR treated animals still had very 
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high miR-451 expression levels in the RBC compartment allowing us to assess the potential role of miR-
451 in hypoxia-induced PAH in a relatively selective manner. 
 
In male rats exposed to hypoxia, silencing of miR-451 by antimiR decreased right ventricular pressure 
compared to controls. This effect was not observed in the RVH or remodelling data from these animals 
however this may be due to the relatively short period of hypoxic exposure chosen as outlined earlier and 
further studies in chronic hypoxia should be repeated. This data indicates that transiently reducing miR-
451 attenuates the development of PAH due to a modest reduction in RVP with exposure to hypoxia. 
Further studies are clearly warranted to study the effects of this approach in a more chronic exposure to 
hypoxia, or indeed alternate rodent models of PAH, such as the hypoxia/sugen model. [38] The original 
study in which miR-451 expression was increased in experimental PAH [4] used the monocrotaline model 
of PAH and it would be interesting to investigate whether transient knock down of miR-451 in the 
monocrotaline rat model of PAH showed a more pronounced reduction in PAH phenotype. In addition, 
hypoxic exposure elevates the haematocrit level and it is known that miR-451 plays in important role in 
erythropoiesis and therefore has an impact on haematocrit. Hence, the monocrotaline model of PAH 
would allow assessment of knocking down miR-451 on PAH phenotype without the additional 
complication of haematocrit regulation by hypoxia. 
 
We did also perform studies assessing chronic knock down of miR-451 using knockout mice. The 
knockout mice displayed high right ventricular pressure, RVH and remodelling in hypoxia similar to wild 
type hypoxic mice. Therefore genetic knock down of miR-451 in this setting appears to have no 
beneficial effect on the development of PAH under the experimental conditions tested. It is difficult to 
ascertain the differences that lead to these conflicting datasets. The finding that we did not observe target 
derepression in lung tissue from either model suggests that alternate targets to the ones tested are 
responsible for the phenotype observed in the rat hypoxia experiment. It is clear also that the rat and 
mouse experiment differ substantially in terms of cell compartments where loss of miR-451 is observed. 
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In the mouse this is global due to the genetic deletion, however, in the antimiR experiments miR-451 
remained at high levels in RBCs. In other tissues we observed very high levels of miR-451 knockdown. 
Due to the important role of miR-451 in erythropoiesis, we cannot rule out interplay of the different 
modulatory systems utilised on lung pathophysiology in the development of PAH. Further studies are 
warranted to fully unpick these important issues.  
 
In vitro data shows that miR-451 promotes hPASMC migration, hence suggesting that knocking down 
miR-451 would reduce PASMC migration in vivo and this could contribute to the attenuated development 
of PAH in the rat hypoxic model. This effect may not have been observed in the hypoxic knockout mouse 
model due to differences in the degree of hypoxic pulmonary vasoconstriction obtained. It has been 
shown recently that physiologically, rats and mice respond differently to hypoxic insult. Hypoxic 
exposure causes sustained rho-kinase dependent vasoconstriction in the rat,[39] while although 
vasoconstriction is an important mechanism involved in mouse hypoxic PAH development, structural 
narrowing of the lumen also plays a critical role.[40] In addition to this, pulmonary vascular remodelling is 
more pronounced in the hypoxic rat compared to the mouse.[41] Therefore the hypoxic mouse model of 
PAH used in this study may not have induced sufficient stimuli (i.e. resulting in PASMC migration) as in 
the rat hypoxic model and hence knocking out miR-451 showed no beneficial effect. This highlights the 
importance in choice of animal model for each study. Of course the benefit of using mice is the ability to 
generate knock-out mice, an important tool in studying the relevance of particular genes, however, the 
moderate PAH phenotype observed in the hypoxic mouse (compared to the hypoxic rat) is something that 
must be taken into consideration when analysing this data.  
 
The observed variation in different model systems may also be due to other pathways/miRNAs 
compensating for the chronic genetic loss of miR-451 in knockout animals. MiRNAs can target hundreds 
of genes [42] and in turn, each specific gene can be modulated by many different miRNAs.[43] However, 
miR-451 has relatively low number of known and predicted targets,[44] thus is limited to the pathways it 
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can potentially modulate. As a result, other miRNAs may have been modulated in the lung that can 
subsequently activate these genes under conditions of prolonged absence of miR-451, i.e. act in a 
compensatory manner for loss of miR-451. There are other cases in which there is disparity between 
genetic ablation and antimiR knock down of a miRNA (reviewed by van Rooij [45]) and this may be down 
to the compensatory pathways mentioned above.  
 
Another reason which may account for the differences between the two in vivo models is gender, and 
PAH is a condition with a gender bias at the clinical level.[46] A microarray carried out by Caruso and 
colleagues [4] studied male rats (both hypoxic and monocrotaline models of PAH) and found that miR-451 
was up-regulated in both disease models. Using hypoxia in the current study, we have observed beneficial 
effects of knocking down miR-451 in male rats with antimiR-451, while no effect was found in female 
knockout mice. Taking this data together, it indicates that miR-451 expression may be gender-dependent 
and the differences in miR-451 expression between the genders requires further investigation. 
 
Taken together, the results of this study demonstrate that transient knockdown of miR-451 expression 
reduces the development of PAH induced by transient exposure to hypoxia. However, genetic deletion of 
miR-451 has no advantageous effect on PAH. Further work is needed to understand the genes targeted by 
miR-451 in the lung in this disease model. 
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Figure Legends 
 
Figure 1: Effect of over-expressing miR-451 on hPASMC proliferation and migration. (A) MiR-451 
expression in hPASMCs after transfection with miR mimic in 15% serum for 72h, as detected by qRT-
PCR. Arbitrary value of 1 assigned to control mimic. Representative graph of two independent 
experiments with technical triplicates, ***p<0.001 vs control mimic. (B) Northern blot analysis of 
hPASMCs as in Figure 1A using a concentration of 10 nM miR mimic, quantified by normalising the 
band intensity of mature miR-451 to the relative U6 signal (n=2 per group), **p<0.01. (C) hPASMC 
thymidine incorporation assay. Representative graph of two independent experiments with four technical 
repeats per condition, ns = non-significant. (D) Representative images of hPASMC scratch wound at 0h 
and 24h. Scale bar = 100µm. Quantification of hPASMC migration assay in 0.1% serum (E) and 15 % 
serum (F). Representative graphs from three independent experiments with technical duplicates, 
***p<0.001 vs control mimic in 0.1% serum. Data analysed by one-way ANOVA followed by Tukey’s 
post-hoc test. 
 
Figure 2: miR-451 and miR-144 expression in rat tissue. Expression of miR-451 (A) and miR-144 (B) 
in rat tissue harvested after pre-treatment with control or antimiR-451 and exposure to normoxic or 
hypoxic conditions for 7 days, as detected by qRT-PCR. Arbitrary value of 1 assigned to the normoxic 
control group for each tissue (n=9 per group). Northern blot (C) was carried out on RNA extracted from 
whole lung and quantified (D) by normalizing the band intensity of mature miR-451 to the relative U6 
signal (n=4 per group). Data analysed using a two-way ANOVA followed by Bonferroni post-hoc test, 
*p<0.05, **p<0.01 and ***p<0.001 vs normoxic control. PA = pulmonary artery, RBC = red blood cells. 
 
Figure 3: Quantification of PAH indices in antimiR-451 treated rats. Quantification of heart rate (A), 
systolic right ventricular pressure (B) and right ventricular hypertrophy (C) in male rats (n=7 per group). 
Pulmonary arterial remodelling quantification (D, n=4-6 per group) and representative pictures stained 
19 
with elastin Van Gieson (E), magnification X40, scale bar = 25µm. Pressures and tissue taken after 7 days 
in normoxic or hypoxic conditions. Data analysed using a two-way ANOVA followed by Bonferroni 
post-hoc test, **p<0.01, ***p<0.001. 
 
Figure 4: Target gene analysis of antimiR-451 treated rats. Target gene expression in frozen lung 
tissue by qRT-PCR for Akt1 (A), Bcl2 (B), Rac1 (C), Tbx1 (D) and Ywhaz (E). Arbitrary value of 1 
assigned to the normoxic control group for each gene (n=9 per group). Data analysed using a two-way 
ANOVA followed by Bonferroni post-hoc test, *p<0.05, **p<0.01. 
 
Figure 5: Quantification of miR-451 expression and PAH indices in miR-451 knockout mice. 
Expression of miR-451 (A) and miR-144 (B) in whole lung tissue from female miR-451 wild type and 
knockout mice, as detected by qRT-PCR (n= 6 per group) and northern blot for miR-451 (C, D) (n=4 per 
group).  Arbitrary value of 1 assigned to the normoxic control group for the qRT-PCR data. 
Quantification of heart rate (E), systolic right ventricular pressure (F), right ventricular hypertrophy (G) 
(n=7-14 per group) and remodelling analysis (H) (n=4-6 per group). Pressures and tissue taken after 14 
days in normoxic or hypoxic conditions. Data analysed by two-way ANOVA followed by Bonferroni 
post-hoc test, *p<0.05 and ***p<0.001. WT = wild type, KO = knockout. 
 
Figure 6: Target gene analysis of miR-451 knockout mice. Target gene expression in frozen lung 
tissue by qRT-PCR for Akt1 (A), Bcl2 (B), Rac1 (C), Rab14 (D), Tbx1 (E) and Ywhaz (F). Arbitrary 
value of 1 assigned to the normoxic miR-451 WT group (n=5-7 per group). Data analysed using a two-
way ANOVA followed by Bonferroni post-hoc test, *p<0.05, **p<0.01 and ***p<0.001. WT = wild type, 
KO = knockout. 
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